Rule 1.126 275. (New) A method of managing pharmaceutical care of a patient comprising the steps of:

providing drug data for a plurality of drugs in a clinical database, each drug having associated therewith a unique identifier comprising a first order representing a therapeutic class of the drug, a second order representing a therapeutic subclass of the drug, and a third order representing the drug;

providing patient data for a plurality of patients in a patient database, the patient data comprising disease states and allergies for each respective patient;

A1

adding to the patient database data representing a therapy regimen of a patient, the therapy regimen comprising at least one prescribed drug, a frequency per day for each respective prescribed drug, a daily dosage for each respective prescribed drug, a date of last dispensing for each respective prescribed drug, a quantity of drug dispensed for each date of last dispensing for each respective prescribed drug, a quantity of drug remaining for each respective prescribed drug, and a compliance percentage;

generating a plurality of progress reports for a patient, each progress report being generated at a different time;

comparing a progress report with a plurality of monitoring parameters; and

modifying the therapy regimen for a patient based upon the comparison of a progress report for the patient with the plurality of monitoring parameters.

26. (New) The method of claim 25, further comprising:

comparing a first progress report with a second progress report, the first progress report being generated earlier in time than the second progress report; and

modifying the therapy regimen for the patient based upon the comparison of the first and second progress reports.

27. (New) The method of claim 25, wherein each unique identifier comprises a plurality of additional orders corresponding to additional information for the drug.

28. (New) The method of claim 25, wherein each unique identifier is linked to one or more disease states identified by an International Classification of Diseases-9 (ICD9) identifier.

29. (New) The method of claim 25, further comprising documenting pharmacist interventions with the patient, wherein the pharmacist interventions comprise clinical interventions, patient-educational interventions, and patient compliance interventions.

30. (New) The method of claim 25, further comprising constructing a therapy plan for the patient based upon an evaluation of the therapy regimen, the therapy plan comprising at

least one medical problem, at least one medical-related goal, at least one course of therapy, and a plurality of monitoring parameters.

8

31. (New) The method of claim 30, further comprising:

analyzing a plurality of surveys submitted by the patient, wherein each answer in a survey is assigned a numerical value, to derive a plurality of results for each survey;

indexing each survey by date of completion;

graphically displaying the results of the surveys, wherein the plurality of surveys is displayed simultaneously; and

modifying the therapy plan based upon the results of the surveys.

9

32. (New) The method of claim 25, further comprising the step of producing a printed report comprising information from the patient database.

10

33. (New) A system for managing pharmaceutical care of patients comprising:

a clinical database comprising drug data entries for a plurality of drugs, each drug data entry having associated therewith a unique identifier, each unique identifier comprising a first order representing a therapeutic class of the drug, a second order representing a therapeutic subclass of the drug, and a third order representing the drug;

a patient database comprising patient data entries for a plurality of patients, each patient data entry comprising a therapy regimen data, a disease state data, and allergy data for each respective patient; and

a program configured to process the drug data entries and the patient data entries, wherein the program retrieves a drug data entry by referring to the unique identifier linked to a drug.

34. (New) The system of claim 33, wherein the program further constructs, tracks and modifies a therapy plan for a patient based upon an evaluation of the therapy regimen data for the patient and the disease state data for the patient.

35. (New) The system of claim 33, wherein each unique identifier comprises a plurality of additional orders representing additional classifications of the drug.

36. (New) The system of claim 33, wherein each unique identifier is linked to one or more disease states identified by an International Classification of Diseases-9 (ICD9) identifier.

37. (New) The system of claim 33, wherein each unique identifier comprises a plurality of characters, the plurality of characters having a first set of characters corresponding to

the first order, a second set of characters corresponding to the second order, and a third set of characters corresponding to the third order.

15

38. (New) The system of claim 37, wherein each unique identifier comprises at least eight characters.

16

39. (New) The system of claim 33, further comprising an integrated database, wherein the clinical database and patient database are maintained within the integrated database.

17

40. (New) The system of claim 33, wherein each therapeutic class of a drug identifies indications, contraindications, recommended dosages, adverse reactions, and drug-drug interactions for the drug.

18

41. (New) The system of claim 33, wherein each therapeutic class comprises therapeutically-related drugs usable for comparable indications.

19

42. (New) The system of claim 33, wherein the therapy regimen data comprises a compliance percentage for a drug, the compliance percentage calculated using the equation:

Compliance Percentage = ((Quantity Dispensed - Quantity Remaining) * 100) / ((Unit Dose * Frequency Per Day) * (Evaluation Date - Date of Last Dispensing)).

43. (New) A method of managing pharmaceutical care of a patient comprising:

prior to the following steps, storing in a clinical database, for each of a plurality of drugs, a list of indications and contraindications for each drug, wherein each drug is linked to the indications and contraindications for that drug via a unique identifier comprising a first order representing a therapeutic class of the drug, a second order representing a therapeutic subclass of the drug, and a third order representing the drug;

storing in a patient database, for each of a plurality of patients, one or more disease states, a therapy regimen, and known allergies;

comparing the therapy regimen of a patient with the disease state of the patient to evaluate the relationship of the therapy regimen and the disease state of the patient; and

constructing a therapy plan for the patient based upon the evaluation, the therapy plan comprising at least one medical problem, at least one medical-related goal, at least one course of therapy, and a plurality of monitoring parameters.

44. (New) The method of claim 43, wherein the therapy regimen comprises at least one prescribed drug, a frequency per day for each respective prescribed drug, a daily dosage for each respective prescribed drug, a date of last dispensing for each respective prescribed drug, a

quantity of drug dispensed for each date of last dispensing for each respective prescribed drug, a quantity of drug remaining for each respective prescribed drug, and a compliance percentage.

45. (New) The method of claim 44, wherein the compliance percentage is calculated using the equation: Compliance Percentage = ((Quantity Dispensed - Quantity Remaining) * 100) / ((Unit Dose * Frequency Per Day) * (Evaluation Date - Date of Last Dispensing)).

46. (New) The method of claim 44, wherein each therapeutic class comprises therapeutically-related drugs usable for comparable indications, and the method further comprises:

comparing a prescribed drug in the therapy regimen with other prescribed drugs to identify prescribed drugs belonging to the same therapeutic class; and

notifying a user if more than one prescribed drug in the same therapeutic class is present in the therapeutic regimen.

47. (New) The method of claim 43, wherein the clinical database further comprises recommended dosages, adverse reactions, and drug-drug interactions for each drug, wherein the recommended dosages, adverse reactions, and drug-drug interactions are linked to each drug by the unique identifier.

48. (New) The method of claim 43, further comprising retrieving the indications and contraindications for a drug by reference to the unique identifier linked to that drug.

Respectfully submitted,

LYON & LYON LLP

Dated: October 4, 2001

By _____
Polaphat Veravanich
Reg. No. 45,179
Attorney for Applicants

633 West Fifth Street, Suite 4700
Los Angeles, CA 90071-2066
(949)567-2300